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Abstract
Aims Toassessbloodglucosecontrolandqualityofhealthcareprovidedtonon-insulin-treatedpatientswithType 2diabetes
mellitus in routine clinical practice in Spain.
Methods Inthisobservational,retrospective,cross-sectionalstudy,patientsweregroupedaseitherhavinggoodorsuboptimal
blood glucose control according to International Diabetes Federation or American Diabetes Association HbA1c goals. Clinical
and socio-demographic data and compliance with the main standard level of care recommendations of the International
Diabetes Federation were recorded during a routine visit. Correlates of glucose control were analysed by logistic regression.
Results Many patients were grouped as having suboptimal control under International Diabetes Federation (61.9%) or
American Diabetes Association (45.0%) criteria. The mean number of accomplished International Diabetes Federation
recommendations (7.3 out of 11) was higher for endocrinologists (than for internists or primary care physicians), and
signiﬁcantly more patients under their care were in the good glucose control group (than with primary care physicians). More
recommendationswereassociatedwithbloodglucosecontrolusingInternationalDiabetesFederationthanAmericanDiabetes
Association criteria, demanding higher quality of health care for achieving stricter goals. Some recommendations were poorly
observed, particularly those concerning patients’ education on diabetes, the prompt prescription of effective treatments and
monitoring of complications. Diabetes complications were associated with being in the suboptimal control group. Patients’
education on diabetes and HbA1c monitoring were associated with being in the good control group.
Conclusions These results demonstrate the need for improvement in the management of patients with non-insulin-treated
Type 2diabetesinactualclinicalpracticeinSpain.SuchimprovementwouldentailastricteradherencetoInternationalDiabetes
Federation recommendations.
Diabet. Med. 28, 731–740 (2011)
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Introduction
Type 2 diabetes mellitus is a chronic, progressive and
heterogeneous disease. Recently, there has been a relevant
increase of incidence of Type 2 diabetes and a noticeable
proportion of patients are not achieving the currently
established glycaemic goals [1]. Intensive research has shed light
onfurtherunderstandingofthedisease,butthecomplexityofthe
underlying metabolic disorders largely impedes its adequate
management. International and national diabetes organizations
have developed evidence-based guidelines for optimal
management of Type 2 diabetes [2–4]. Although both
improving diabetes care and providing intensive blood glucose
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management costs, they are cost-effective over a patient’s
lifetime because of the substantially reduced cost of
complications, increased time free of complications and
improved quality-adjusted life years [5,6]. It is thus crucial to
search for effective strategies to improve the currently
unsatisfactory clinicalframeof Type 2 diabetes.
Controlling hyperglycaemia is one of the therapeutic
goals [1,3,4], but it is well recognized that optimal
management of Type 2 diabetes also requires overall
metabolic control related to its multiple co-morbidities in
order to prevent long-term macro- and microvascular
complications [7–11].
Recommendations of care are thus directed toward adequate
management of Type 2 diabetes disorders, as well as the
prevention or amelioration of associated complications [2–4].
These recommendations include: education on diabetes for
patients (providing knowledge of the disease and counselling for
self-management); promotion for the achievement and
maintenance of HbA1c goals; appropriate application of
lifestyle interventions and pharmacological therapies; moni-
toringofbloodglucoseandpressurelevels,lipidproﬁleandother
cardiovascular risk factors; and routinely performing eye,
kidney, feet and sensorimotor neuropathy examinations. All
these recommendations are reasonably achievable in routine
clinical practice and should be readily available to patients with
Type 2 diabetes attending healthcare facilities.
This observational study investigated whether blood glucose
controlisrelatedtothequalityofhealthcareprovidedtopatients
with non-insulin-treated Type 2diabetes and also assessed other
factors that might inﬂuence the achievement of current HbA1c
goals.
Patients and methods
This nationwide, multi-centre, naturalistic, observational,
retrospective, cross-sectional study evaluated patients with
Type 2 diabetes in routine clinical settings in Spain. The
investigators were endocrinologists, internists and primary care
physicians with prior experience in clinical research who
included patients in the same chronological order as they
attended their outpatient clinics. To obtain a representative
sample, the geographical distribution of study sites was
proportional to the 2005 Spanish census and balanced among
the three medical specialties concerned. During the 3-month
inclusion period, retrospective (medical histories since diagnosis
of Type 2 diabetes) and cross-sectional (the routine visit during
which the patient was included in the study),socio-demographic
and clinical data were recorded using structured case report
forms.
This study complied with the International Conference on
Harmonization’s Good Clinical Practice guidelines and Spanish
regulatory requirements. The protocol was approved by an
accredited institutional ethicscommittee.Allpatientssigned and
dated written informed consent forms.
The inclusion criteria for patients were: male or female; aged
‡ 30 years; diagnosed with Type 2 diabetes according to the
AmericanDiabetesAssociation(ADA)guidelines[12];notbeing
treated with insulin; and having clinical records available at the
study centres.Pregnantwomen and patientswith a diabetestype
other than Type 2 [12] were not eligible.
The primary objective was to evaluate the blood glucose
control of patients with non-insulin-treated Type 2 diabetes in
relationtothequalityofhealthcaretheyreceived,determinedby
the accomplishment of the main International Diabetes
Federation (IDF) recommendations for the standard level of
care [2]. Patients were grouped as achieving good blood glucose
control[£ 6.5%(£ 48 mmol⁄mol) [13] or£ 7.0%(£ 53mmol⁄
mol) [13]] vs. suboptimal blood glucose control [> 6.5%
(> 48 mmol⁄mol) or > 7.0% (> 53 mmol⁄mol)] according to
IDF [2] or ADA [4] HbA1c goals, respectively. Secondary
objectives were to evaluate different features of these groups:
(i) socio-demographic and clinical data; (ii) therapeutic
regimens; (iii) metabolic control; (iv) prevalence of diabetes
complications; and (v) distribution by the type of specialist
providing health care.
The IDF recommendations for standard level of care assessed
in this study are listed in Fig. 1. The IDF’s recommendation
regarding the initiation of insulin therapy was not included
because insulin-treated patients were not eligible. However, the
number of patients who initiated insulin therapy at the cross-
sectional visit was recorded.
Statistical analyses
At least 2170 patients were required (1085 patients each group),
assuming that patients were evenly distributed (50%) between
the group with good blood glucose control and the group
with suboptimal blood glucose control. This sample size
would detect ‡ 6% between-group differences in the
proportions accomplishing the IDF standard level of care
recommendations, with 80% statistical power and a 5%
signiﬁcance level. The participation of 250 investigators,
recruiting 10 patients each, was planned to compensate for
missing or non-evaluable data.
Data were summarized using descriptive statistics. The
recommendations for cardiovascular risk assessment and eye
examinations were considered accomplished if performed at
least annually. The time to the ﬁrst change of pharmacological
therapy was estimated by the Kaplan–Meier method.
Two logistic regression analyses were performed to evaluate
whichfactorsmightrelatetobeingineithergroup,usinggoodvs.
suboptimal blood glucose control as the dependent variable,
under either IDF or ADA criteria. The independent variables
were the compliance with the 11 main IDF standard levelof care
recommendations (yes vs. no) and some derived from the socio-
demographic, clinical and healthcare data, including physicians’
specialties, that, in prior bivariate analyses regarding glycaemic
control, showed a < 10% signiﬁcance level. Different models
were tested progressively to exclude those independent variables
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signiﬁcant by the likelihood ratio test.
Missing data from the variables required to evaluate the
primary objective were imputed by the worst-case method as
follows:(i)thelastvalueofHbA1cwasusedandpatientswithno
available data within the previous 6 months were placed in the
suboptimal blood glucose control group and (ii) missing data on
an IDF recommendation were imputed as not accomplished.
Inferences were made at a 5% signiﬁcance level. SAS
version 8.02 software (SAS Institute, Cary, NC, USA) was used
for the statistical analyses.
Sensitivity analyses evaluated possible differences between the
population of patients with no missing data for the variables
required to assess the primary objective (n = 1514, observed
population)andthepopulationofpatientsincludedperprotocol
(n = 2266, total population).
Results
Between March and May 2007, 220 investigators collected data
from 2271 patients. Investigators were endocrinologists (37%),
internists (31%) and primary care physicians (32%). Data from
2266 patients were analysed. Patients’ disposition is depicted in
Fig. 2 and their characteristics are summarized in Table 1 (by
blood glucose control) and Table 2 (by medical specialty). A
number of patients were grouped as having suboptimal blood
glucose control by IDF (61.9%) or ADA (45.0%) criteria.
Proportions of patients in the suboptimal blood glucose control
group were higher among those treated by primary care
physicians (64.5⁄50.6%, IDF⁄ADA criteria), followed by those
treated by internists (60.6⁄43.5%) and endocrinologists
(60.8⁄41.4%). Nearly all patients (93.9%) were treated with
both diet and pharmacological therapy. The oralhypoglycaemic
agents most frequently prescribed were metformin and
glibenclamide for the ﬁrst received treatment and metformin
and glimepiride for the second treatment, both alone
(monotherapy) or in combination. Less than 10% patients
received other treatments. The time to the ﬁrst change of
pharmacological therapy was similar, but slightly longer, in
patients in the good vs. suboptimal blood glucose control group
(respective median Kaplan–Meier point estimates: 3.9 vs.
3.5 yearsforIDFcriteria and 3.7 vs.3.4 yearsforADAcriteria).
More patients with secondary or higher academic levels were
in the good vs. suboptimal control group, whereas the opposite
occurred among patients without any academic grade (Table 1).
Interestingly,historicalHbA1clevelswerehigheramongpatients
in the suboptimal blood glucose control group at each treatment
change (Table 1). When the ADA criteria for blood glucose
controlwereappliedtodeﬁnethegroupsinstead,theresultswere
quite similar to those provided for the groups formed by IDF
criteria, with the exception that the proportion of patients in the
ADA good control group with diabetes complications was
greater, as were the mean HbA1c values in both groups (ﬁrst, last
andthoseateachtreatmentchange),correspondingtothehigher
cut-off value using the ADA criteria. Irrespective of glycaemic
control, mean values of HDL cholesterol and triglycerides were
within the normal ranges, but LDL cholesterol was above
optimal level. More than two-thirds of patients were
hypertensive.
Patients’ characteristics differed among medical specialties
also (Table 2). Patients treated by primary care physicians had
shorter diabetes duration, lower academic level, were more
FIGURE 1 International Diabetes Federation’s recommendations for standard care assessed in this study. *Diabetes education refers to participation in non-
evaluated, structured training sessionsabout diabetescourse andcomplications,the therapeuticoptionsavailableandself-carestrategiesthatimprovegeneral
therapeuticeffectiveness.Thesesessionswereconductedbyaspecializednurseand,lessfrequently,byaspecialisedphysician.Becausetherewasnotaprotocol
for these sessions, their contents varied from one site to another.
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aloneandhadfewerdiabetescomplicationsthanthosetreatedby
other specialists. Endocrinologists changed diabetes treatments
more frequently.
CompliancewithIDFstandardlevelofcarerecommendations
is presented in Fig. 3. Compliance was higher for recommended
blood pressure measurement (96.8%), with similar fulﬁlment in
the two groups, and annual proteinuria test (86.3%), which was
accomplishedbymorepatientsinthegoodbloodglucosecontrol
group. Cardiovascular risk-factor assessment (34.3%) and
advice about beneﬁts of HbA1c level £ 6.5% (£ 48 mmol⁄mol)
(48.3%) had the lowest compliance rates. The other
recommendations showed compliance rates ranging between
56.2 and 70.2%. With the exception of self-monitoring of blood
glucose and the start of oral hypoglycaemic agent therapy when
diet alone is insufﬁcient, all recommendations were fulﬁlled by a
greater proportion of patients in the good control group than in
the suboptimal control group. The mean number of
accomplished recommendations was 7.3 out of 11; by
specialties, patients treated by endocrinologists fulﬁlled more
(Table 2, Fig. 3). Delivery of structured education programmes
on diabetes, advice on HbA1c and reproductive counselling were
comparatively scarce among patients treated by internists, and a
low proportion of patients treated by primary care physicians
haddocumentationofregularandfrequentHbA1cmonitoringor
self-monitoring of blood glucose.
Sensitivity analyses showed similar socio-demographic and
clinical data in the total and observed populations (data not
shown). The differences were minimal regarding blood glucose
control grouping, indicating that slightly more patients
qualifying for the good blood glucose control group were in the
observed population (57.1%) than in the total population
(55.0%), which was expected after imputing the data using the
worst-case method.
ResultsoflogisticregressionanalysesareillustratedinTable 3.
Because HbA1c values at or near diabetes diagnosis were not
FIGURE 2 Patient disposition. ADA, American Diabetes Association; IDF, International Diabetes Federation.
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models.Theseanalysesrevealedthatpatientsreceivingeducation
on diabetes, undergoing regular HbA1c determinations, having
secondary or higher academic levels and being treated with diet
alonehad a greaterlikelihood ofbeing inthegood bloodglucose
control group under IDF criteria. Only HbA1c monitoring
indicated a greater likelihood of being in the good control group
under ADA criteria. Conversely, patients starting oral
hypoglycaemic agent therapy, receiving advice about the
importance of maintaining HbA1c £ 6.5% (£ 48 mmol⁄mol)
Table 1 Patient and Type 2 diabetes treatment characteristics according to blood glucose control per the International Diabetes Federation (IDF) and the
American Diabetes Association (ADA) criteria
HbA1c IDF criteria HbA1c ADA criteria
£ 6.5%
(£ 48 mmol⁄mol)
(n = 863)
> 6.5%
(> 48 mmol⁄mol)
(n = 1403)
£ 7.0%
(£ 53 mmol⁄mol)
(n = 1247)
> 7.0%
(> 53 mmol⁄mol)
(n = 1019)
Age, years, mean (sd) 64.1 (11.0) 64.6 (11.2) 64.2 (10.9) 64.6 (11.5)
Years since diagnosis, mean (sd) 6.8 (6.6) 7.9 (6.4) 7.1 (6.5) 7.9 (6.5)
Female gender, n⁄N (%) 400⁄863 (46.3) 671⁄1403 (47.8) 584⁄1247 (46.8) 487⁄1019 (47.8)
Body mass index, kg⁄m
2, mean (sd) 29.9 (5.3) 30.2 (5.2) 29.9 (5.3) 30.3 (5.1)
Type 2 diabetes family history, n⁄N (%) 461⁄767 (60.1) 789⁄1230 (64.1) 685⁄1109 (61.8) 565⁄888 (63.3%)
Race*
Caucasian, n⁄N (%) 811⁄862 (94.1) 1306⁄1399 (93.4) 1168⁄1245 (93.8) 949⁄1016 (93.4)
Latin American⁄others, n⁄N (%) 51⁄862 (5.9) 93⁄1399 (6.6) 77⁄1245 (6.2) 67⁄1016 (6.6)
Academic level*
Without any grade certiﬁcate, n⁄N (%) 147⁄863 (17.0) 323⁄1400 (23.1) 217⁄1247 (17.4) 253⁄1016 (24.9)
Primary, n⁄N (%) 389⁄863 (45.1) 668⁄1400 (47.7) 571⁄1247 (45.8) 486⁄1016 (47.8)
Secondary⁄higher, n⁄N (%) 326⁄863 (37.8) 409⁄1400 (29.2) 458⁄1247 (36.7) 277⁄1016 (27.3)
Smoker⁄ex-smoker, n⁄N (%) 307⁄860 (35.7) 507⁄1399 (36.2) 457⁄1243 (36.8) 357⁄1016 (35.1)
Hypertension, n⁄N (%) 547⁄863 (63.4) 933⁄1403 (66.5) 801⁄1247 (64.2) 679⁄1019 (66.6)
SBP, mmHg, mean (sd) 134.6 (16.7) 137.6 (17.4) 135.1 (16.5) 138.1 (18.0)
DBP, mmHg, mean (sd) 76.8 (9.8) 78.4 (10.0) 77.2 (9.7) 78.5 (10.2)
Dyslipidaemia, n⁄N (%) 541⁄863 (62.7) 923⁄1403 (65.8) 780⁄1247 (62.6) 684⁄1019 (67.1)
LDL cholesterol, mmol⁄l, mean (sd) 2.9 (0.8) 3.0 (0.9) 2.9 (0.8) 3.0 (0.9)
HDL cholesterol, mmol⁄l, mean (sd) 1.3 (0.5) 1.3 (0.6) 1.3 (0.5) 1.3 (0.6)
Triglycerides, mmol⁄l, mean (sd) 1.6 (1.1) 1.8 (1.1) 1.6 (1.1) 1.8 (1.2)
Diabetes complications, n⁄N (%) 266⁄860 (30.9) 522⁄1395 (37.4) 403⁄1240 (32.5) 385⁄1015 (37.9)
First HbA1c value, %, mean (sd) 7.1 (1.6) 7.8 (1.6) 7.2 (1.5) 7.9 (1.6)
mmol⁄mol, mean (sd) 54 (17) 62 (17) 55 (16) 63 (17)
Last HbA1c value, %, mean (sd) 5.9 (0.6) 7.6 (1.0) 6.2 (0.6) 8.0 (1.0)
mmol⁄mol, mean (sd) 41 (7) 60 (11) 44 (7) 64 (11)
Last FPG value, mmol⁄l, mean (sd) 7.1 (1.6) 8.6 (2.4) 7.2 (1.6) 8.9 (2.5)
Current Type 2 diabetes treatment*
No treatment, n⁄N (%) 1⁄863 (0.1) 1⁄1403 (0.1) 1⁄1247 (0.1) 1⁄1019 (0.1)
Diet only, n⁄N (%) 60⁄863 (7.0) 45⁄1403 (3.2) 73⁄1247 (5.9) 32⁄1019 (3.1)
Drugs only, n⁄N (%) 5⁄863 (0.6) 27⁄1403 (1.9) 10⁄1247 (0.8) 22⁄1019 (2.2)
Diet + drugs, n⁄N (%) 797⁄863 (92.4) 1330⁄1403 (94.8) 1163⁄1247 (93.3) 964⁄1019 (94.6)
At least one treatment change, n⁄N (%) 345⁄702 (49.1) 733⁄1165 (62.9) 537⁄1018 (52.8) 541⁄849 (63.7)
Monotherapy as ﬁrst treatment, n⁄N (%) 611⁄702 (87.0) 1027⁄1165 (88.2) 900⁄1018 (88.4) 738⁄849 (86.9)
Monotherapy as second treatment, n⁄N (%) 83⁄324 (25.6) 157⁄711 (22.1) 123⁄509 (24.2) 117⁄526 (22.2)
HbA1c at start of diet, %, mean (sd) 7.2 (1.6) 7.9 (1.5) 7.4 (1.5) 8.0 (1.6)
mmol⁄mol, mean (sd) 55 (17) 63 (16) 57 (16) 64 (17)
HbA1c at start of OHA monotherapy, % 7.3 (1.4) 8.1 (1.4) 7.5 (1.3) 8.2 (1.4)
mmol⁄mol, mean (sd) 56 (15) 65 (15) 58 (14) 66 (15)
HbA1c at start of two OHAs combined, % 7.7 (1.4) 8.1 (1.2) 7.7 (1.2) 8.3 (1.2)
mmol⁄mol, mean (sd) 61 (15) 65 (13) 61 (13) 67 (13)
HbA1c at start of three OHAs combined, % 7.8 (1.2) 8.2 (1.0) 7.9 (1.1) 8.3 (1.0)
mmol⁄mol, mean (sd) 62 (13) 66 (11) 63 (12) 67 (11)
Started insulin at study visit, n⁄N (%) 12⁄852 (1.4) 139⁄1362 (10.2) 20⁄1227 (1.6) 131⁄987 (13.3)
Accomplished IDF recommendations, mean (sd) 7.3 (2.3) 7.2 (2.3) 7.4 (2.3) 7.1 (2.3)
*Stratiﬁed variables; percentages add up to 100% within each group.
Transformed values for HbA1c. The original values (in %) are in the row immediately above.
 N Number of patients with data available.
DBP, diastolic blood pressure; FPG, fasting plasma glucose; OHA, oral hypoglycaemic agent; SBP, systolic blood pressure.
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likelihood of being in the good glycaemic control group. Also
demonstrating a lower likelihood of good glycaemic control (by
IDF and⁄or ADA criteria) were patients with: a family history of
Type 2 diabetes; higher systolic blood pressure, fasting plasma
glucose and total cholesterol levels; diabetes complications; or
treatmentbyprimarycarephysicians.Intheobservedpopulation
(data not shown), associations were less evident. There were
fewer patients in the suboptimal blood glucose control group in
this population because no data were imputed by the worst-case
method.
Discussion
Thisobservationalstudyevaluatedabundantsocio-demographic
and clinical data from patients with non-insulin-treated Type 2
diabetes in outpatient practices in Spain. Blood glucose control
was suboptimal in approximately one in two patients,
reinforcing the notion that adequate control is very difﬁcult to
achieve [4]. Compliance with the IDF recommendations for the
standard level of care was moderate and only approximately
one in ten patients with suboptimal control started insulin
therapy at the cross-sectional evaluation. A higher proportion
of patients with good blood glucose control accomplished
a majority of the recommendations. Regression analyses
conﬁrmed the association between blood glucose control and
accomplishment of care recommendations and also revealed
associations between patients’ academic backgrounds and the
settings where their care takes place (primary vs. specialized
outpatient consultations).
Becausetwodifferentcut-offswereanalysed,thisresearchcan
providesomecomparativedataonhowthedifferentHbA1cgoals
relates to the quality of health care. The present results suggest
that the stricter the glycaemic goal used for deﬁning adequate
control,thestrongertheassociationbetweenthequalityofhealth
care and blood glucose control. The most recent editions of
therapeutic recommendations advocate the use of ﬂexible goals
to the control of hyperglycaemia [4], based in part on the
dissipation of the concerns regarding the risk–beneﬁt ratio of
intensiﬁedbloodglucosecontrol.Thisstudyaddsthatthestricter
Table 2 Patient and characteristics of Type 2 diabetes treatment according to the medical specialty of the treating physician
Endocrinology
(n = 841)
Internal medicine
(n = 703)
Primary care
(n = 722)
Age, years, mean (sd) 62.4 (10.8) 66.3 (11.0) 65.0 (11.4)
Years since diagnosis, mean (sd) 8.5 (7.2) 7.2 (6.4) 6.6 (5.5)
Female gender, n⁄N (%) 417⁄841 (49.6) 311⁄703 (44.2) 343⁄722 (47.5)
Race*
Caucasian, n⁄N (%) 813⁄836 (97.3) 659⁄703 (93.7) 645⁄722 (89.3)
Latin American⁄others, n⁄N (%) 23⁄836 (2.8) 44⁄703 (6.2) 77⁄722 (10.7)
Academic level*
Without any grade certiﬁcate, n⁄N (%) 144⁄840 (17.1) 136⁄703 (19.4) 190⁄720 (26.4)
Primary, n⁄N (%) 383⁄840 (45.6) 335⁄703 (47.7) 339⁄720 (47.1)
Secondary⁄higher, n⁄N (%) 312⁄840 (37.1) 232⁄703 (33.0) 191⁄720 (26.5)
Smoker⁄ex-smoker, n⁄N (%) 298⁄836 (35.7) 273⁄702 (38.9) 243⁄721 (33.7)
Hypertension, n⁄N (%) 514⁄841 (61.1) 498⁄703 (70.8) 468⁄722 (64.8)
SBP, mmHg, mean (sd) 135.6 (18.0) 138.1 (18.5) 135.9 (14.8)
DBP, mmHg, mean (sd) 77.3 (9.7) 78.6 (10.9) 77.5 (9.1)
Dyslipidaemia, n⁄N (%) 552⁄841 (65.6) 471⁄703 (66.7) 441⁄722 (61.1)
LDL cholesterol, mmol⁄l, mean (sd) 2.8 (0.8) 2.9 (0.9) 3.1 (0.8)
HDL cholesterol, mmol⁄l, mean (sd) 1.3 (0.4) 1.2 (0.4) 1.3 (0.7)
Triglycerides, mmol⁄l, mean (sd) 1.6 (1.0) 1.8 (1.3) 1.7 (1.1)
Diabetes complications, n⁄N (%) 304⁄837 (36.2) 284⁄700 (40.6) 200⁄718 (27.9)
Last HbA1c value, %, mean (sd) 6.9 (1.1) 6.9 (1.3) 6.8 (1.1)
mmol⁄mol, mean (sd) 52 (12) 52 (14) 51 (12)
Last FPG value, mmol⁄l, mean (sd) 8.0 (2.2) 8.0 (2.4) 7.9 (2.0)
Current Type 2 diabetes treatment*
No treatment, n⁄N (%) 1⁄841 (0.1) 0⁄703 (0.0) 1⁄722 (0.1)
Diet only, n⁄N (%) 20⁄841 (2.4) 28⁄703 (4.0) 57⁄722 (7.9)
Drugs only, n⁄N (%) 13⁄841 (1.6) 14⁄703 (2.0) 5⁄722 (0.7)
Diet + drugs, n⁄N (%) 807⁄841 (96.0) 661⁄703 (94.0) 659⁄722 (91.3)
At least one treatment change, n⁄N (%) 450⁄697 (64.6) 334⁄594 (56.2) 294⁄576 (51.0)
Monotherapy as ﬁrst treatment, n⁄N (%) 573⁄697 (82.2) 538⁄594 (90.6) 527⁄576 (91.5)
Accomplished IDF recommendations, mean (sd) 8.0 (2.1) 6.8 (2.5) 6.9 (2.2)
*Stratiﬁed variables; percentages add up to 100% within each group.
Transformed values for HbA1c. The original values (in %) are in the row immediately above.
 N Number of patients with data available.
DBP, diastolic blood pressure; FPG, fasting plasma glucose; IDF, International Diabetes Federation; SBP, systolic blood pressure.
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insulin therapy, might serve to improve blood glucose control
among patients with Type 2 diabetes.
The relevant role of HbA1c monitoring has been consistently
recognized in parallel with the long-term beneﬁts of HbA1c
control [1,3,4,9,11]. This study contributes evidence regarding
its actual value under routine clinical practice conditions in a
non-selected and heterogeneous sample of patients with Type 2
diabetes. Less clear, however, is the relationship between
education on diabetes and blood glucose control. Beneﬁts that
aresigniﬁcantonlyintheshorttermandarerestrictedtoselected
subgroups of patients have been reported [14,15], albeit factors
such as the longer duration of programmes and a higher
frequency of face-to-face patient-educator contacts have been
noted to favour positive outcomes [15,16]. The results reported
here supportthe generic beneﬁtofeducationon diabetes,despite
the heterogeneity of programmes used, underscoring its role in
improvingoutcomesacrossthediverserangeofpatientsincluded
in this sample. It also supports the notion that psychological
barriers,whicharemainlyrelatedtothestrictnessofthediabetes
regimen and are responsive to educational techniques, are
relevant impediments to the implementation of diabetes care
[17,18]. Compared with the difﬁculties in deploying and
maintaining lifestyle changes in primary diabetes prevention
trials[19],thepresentresultssuggestthatthebeneﬁtofeducation
on diabetes is more certain in patients with Type 2 diabetes than
in individuals in the pre-diabetic range. As mentioned, the
programmes used here were not homogeneous. It is thusfeasible
that even better results would be expected if a uniform protocol
for diabetes education was developed and deployed in Spain, as
occurred in other countries [20]. Lastly, together with education
on diabetes, there was an association between higher academic
backgroundandgoodbloodglucosecontrol.Althoughacademic
level differs from education on diabetes, it is reasonable to think
that more literate patients might learn more easily or be more
knowledgeable about diabetes.
The paradoxical association between starting oral
hypoglycaemic agent therapy when lifestyle interventions alone
areinsufﬁcient,performingself-monitoringofbloodglucoseand
advising patients regarding the beneﬁts of achieving glycaemic
targets with suboptimal blood glucose control does not
necessarily indicate a negative contribution by these
recommendations. Patients with suboptimal control showed
consistently higher HbA1c values from the point of disease
diagnosis, with negligible variation among them (contrasting
with relevant reductions in patients with good blood glucose
control), and more of those patients needed oral hypoglycaemic
agenttherapy,includingmoretherapeuticchangesandinitiation
ofinsulintherapy.HigherHbA1cvaluesateachtreatmentchange
mightsuggesta fasterdiseaseprogression orgreaterresistance to
treatments, despite the efforts to augment treatment when
control is inadequate. Following this reasoning, patients with
suboptimalcontrolwouldhaverequiredmoreinsistentguidance
regarding blood glucose control awareness than patients
consistently meeting glycaemic goals, hence explaining the
relationship between these factors and suboptimal blood
FIGURE 3 Compliance with IDF recommendations according to glycaemic control per the IDF criteria and to the treating physician’s specialty. BP, blood
pressure; CV, cardiovascular; IDF, International Diabetes Federation; OHA, oral hypoglycaemic agent.
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recommendations was optimal. If there is a subset of patients
exhibiting distinct and more aggressive disease progression, for
examplearapidlossofB-cellfunction,effortsshouldbemadeto
promptly identify and intensify therapeutic measures, as they
may be of particular beneﬁt in these individuals [21].
Thelowerlikelihoodofgoodbloodglucosecontrolofpatients
treated by primary care physicians with respect to those treated
by endocrinologists, despite having a shorter duration of
diabetes, raises a concern, because the majority of Type 2
diabetes care is delivered at the primary care level. Structural
factors that have been identiﬁed as affecting the quality of
diabetes care by primary care physicians in the USA more than
10 yearsago(suchaslackoftimeandotherresourcestoperform
recommended procedures, or a busy primary clinic) [22] in all
probability currently exist in Spain and in other European
countries. In addition to the technical quality of care, which was
the focus of this study, environmental factors and other external
determinants, the so-called service quality, may also affect the
global quality of health care [23]. Different approaches for
improving the quality of Type 2 diabetes in primary care have
shownpositiveoutcomes[6,24,25].Thefactthatpatientstreated
by endocrinologists, compared with those treated by primary
care physicians, had a longer disease progression and more
diabetes complications despite being younger suggests that they
feature a more challenging clinical proﬁle. It is feasible that
endocrinologists preferentially treat patients who are referred
because they require a more thorough evaluation and care. Yet
theirbetterachievementofglycaemicgoalshighlightsthatthereis
considerable room for improvement in the primary care setting.
Theinterventionsmadebyendocrinologiststoimprovecontrolin
patientswithaprogresseddiseasemightbeofgreaterhelpifthey
were carried out at an earlier stage [7]. Given the potential long-
termbeneﬁtsofdelayingorpreventingdiabetescomplicationsby
early interventions, further research on this topic is required.
Failure to comply with blood pressure and lipid targets was
common, as denoted by the mean values of systolic blood
pressure and LDL cholesterol above their normal ranges. Better
management of hypertension and dyslipidaemia, together with
bloodglucosecontrol,isrecommendedprovidedthatsubstantial
reductions in cardiovascular risk can be achieved [4,8]. The
achievementofHDLcholesteroltargets,incontrastwithreports
Table 3 Results of the logistic regression of having good blood glucose control as per the criteria of the International Diabetes Federation (IDF) and the
American Diabetes Association (ADA)
Independent variables
IDF (HbA1c £ 6.5 vs. > 6.5%)
(£ 48 vs. > 48 mmol⁄mol)
OR (95% CI)§
ADA (HbA1c £ 7.0 vs. > 7.0%)
(£ 53 vs. > 53 mmol⁄mol)
OR (95% CI)§
Standard care (yes vs. no)
Education on diabetes 1.54 (1.10–2.14)* 1.15 (0.84–1.56)
Advice about HbA1c level 0.65 (0.47–0.90)* 1.02 (0.76–1.38)
Frequent HbA1c monitoring (2–6 months) 1.39 (1.05–1.84)* 1.59 (1.26–2.00)*
Self monitoring blood glucose 0.73 (0.58–0.92)* 0.85 (0.69–1.06)
Timely start of OHA therapy 0.50 (0.39–0.63)* 0.62 (0.50–0.77)*
Regular blood pressure measurement 1.19 (0.59–2.40) 1.02 (0.58–1.80)
Annual CV risk assessment 1.03 (0.82–1.29) 0.95 (0.77–1.17)
Annual eye examination 1.00 (0.79–1.27) 0.91 (0.73–1.13)
Annual proteinuria measurement 1.30 (0.90–1.86) 1.38 (0.99–1.90)
Annual feet examination 1.14 (0.83–1.57) 0.93 (0.69–1.24)
Neuropathy screening 1.02 (0.74–1.39) 1.13 (0.85–1.51)
Primary care physician vs. endocrinologist 0.77 (0.58–1.03) 0.69 (0.53–0.89)*
Internist vs. endocrinologist 0.99 (0.76–1.30) 0.98 (0.76–1.25)
Secondary⁄higher vs. other academic background 1.29 (1.03–1.61)* 1.23 (0.99–1.52)
Time from diabetes diagnosis 0.99 (0.97–1.00) —
Type 2 diabetes family history (yes vs. no) 0.80 (0.64–1.00)* —
Last FPG value 0.98 (0.97–0.98)* 0.98 (0.97–0.98)*
Last SBP value 0.99 (0.98–0.99)* 0.99 (0.99–1.00)
Last total cholesterol value — 0.99 (0.99–0.99)*
Number of blood lipid measurements in the last 2 years 1.05 (1.00–1.11) —
Diet alone vs. diet + drug therapy 1.70 (1.03–2.81)* 1.58 (0.96–2.58)
Drug alone vs. diet + drug therapy 0.40 (0.13–1.22) 0.35 (0.14–0.85)*
Diabetes complications (present vs. absent) 0.82 (0.65–1.04) 0.78 (0.63–0.96)*
CV risk factors (present vs. absent) 0.70 (0.41–1.22) —
*Signiﬁcant association.
For categorical variables, the last category is the reference category.
 Accomplishment of one of the IDF recommendations was not included in the logistic regression because it only concerned women.
§An odds ratio > 1 indicates a greater chance of having good glycaemic control; an odds ratio < 1 indicates a lower chance of having good
glycaemic control.
CV, cardiovascular; FPG, fasting plasma glucose; OHA, oral hypoglycaemic agent; SBP, systolic blood pressure.
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related to Mediterranean dietary habits. Prior investigations on
the SpanishsampleoftheDiabetesNutrition andComplications
Trial (DNCT) also showed optimal HDL cholesterol and
triglyceride levels, which might be explained by the observance
of healthy unsaturated to saturated fatty acid ratios [27,28],
despite poor global adherence to nutritional recommendations
[27–29]. This is an issue of interestbecause stronger associations
have been suggested between fatty acid ratios in the diet and
deferral of complications than with absolute unsaturated fatty
acid consumption [27].
This study has strengths and limitations. Its large sample size
and the inclusion of different specialists’ care provide a reliable
representation of the Spanish patients with non-insulin-treated
Type 2 diabetes. Conversely, the national scope of the study
being restricted to Spain prevents international extrapolation of
the results, particularly to countries with different dietary
habits, which is a signiﬁcant inﬂuence on diabetes outcomes
[1,4]. The retrospective character of the study also constitutes a
limitation, mainly attributable to the lack of certain
management details (e.g. intervals between treatment
changes), more precise information about dietary patterns of
patients and the large amount of missing data for HbA1c values
at diabetes diagnosis.
In conclusion, this study has shown there is insufﬁcient
compliancewiththeIDFstandardlevelofcarerecommendations
for Type 2 diabetes in real clinical practice in Spain. With
approximately half of patients failing to achieve adequate blood
glucose control, a stricter adherence to these recommendations,
particularlyintheprimarycaresetting,isrecommendedbasedon
this investigation, provided that they are associated with
improved metabolic control.
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